557795-19-4 Sunitinib, Free base AKSci L781
 
 
Loading Please Wait...
  L781    AKSci Reference Standard
Sunitinib, Free base
, 99% (HPLC), powder
 
5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide




IDENTITY
CAS Number:557795-19-4
MDL Number:MFCD09260778
MF:C22H27FN4O2
MW:398.47
SPECIFICATIONS & PROPERTIES
Purity:99% (HPLC), powder
Spectra:NMR, LCMS, FT-IR, HPLC
Physical Form:Orange-yellow powder
Melting Point:229-242°C
Long-Term Storage:Store at room temperature
HAZARDOUS MATERIALS INFORMATION
Not hazardous material

REVIEW

 Sunitinib is a small molecule that inhibits multiple RTKs, some of which are implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor of platelet-derived growth factor receptors (PDGFRa and PDGFRb), vascular endothelial growth factor receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3 (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.

REFERENCES
[1]Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24.
[2] Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38.

GHS

Pictograms

Signal Word
Danger

Hazard Statements
H360; H372

Precautionary Statements
P201; P202; P260; P264; P270; P281; P308+P313; P405; P501


Current as of August 9, 2020

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.


CATEGORIES

 Heterocyclic Building Blocks > Pyrroles, Indoles, Amines, Fluorine, Carboxylic Acids, Ketones, Amides


PubChem